Steven Greenberg

Steven Greenberg

Company: Bristol Myers Squibb

Job title: Vice President, Disease Area Head, Pulmonology


Phase 2 Study Results for Agents That Target LPA1 & JNK1 in Pulmonary Fibrosis 9:00 am

Comparing BMS-986278 (LPA1 antagonist) and CC-90001 (JNK1 inhibitor) programs in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): scientific rationale; study designs Key results from BMS-986278 and CC-90001 phase 2 trials Looking to phase 3 for the LPA1 programRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.